Does the media refer more to ORIC or ACAD?

In the previous week, ACADIA Pharmaceuticals had 21 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 12 mentions for Oric Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of 0.27 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 12 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ORIC or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Celcuity N/A N/A -$177.04M -$3.90 N/A

Is ORIC or CELC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Celcuity N/A -244.61% -50.22%

Does the media prefer ORIC or CELC?

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Oric Pharmaceuticals and 7 mentions for Celcuity. Oric Pharmaceuticals' average media sentiment score of 0.27 beat Celcuity's score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ORIC or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is ORIC or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Parabilis Medicines N/A N/A N/A

Is ORIC or TNGX more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Tango Therapeutics N/A -41.54% -33.44%

Does the media prefer ORIC or TNGX?

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for Oric Pharmaceuticals and 7 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.81 beat Oric Pharmaceuticals' score of 0.27 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ORIC or VKTX?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is ORIC or VKTX more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Viking Therapeutics N/A -94.56% -82.75%

Does the media refer more to ORIC or VKTX?

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 12 articles in the media. Viking Therapeutics' average media sentiment score of 1.12 beat Oric Pharmaceuticals' score of 0.27 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oric Pharmaceuticals (ORIC) Competitors

$13.50 +0.57 (+4.41%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$12.38 -1.12 (-8.33%)

As of 08/7/2026 08:00 PM Eastern

Compare

ORIC vs. ACAD, CELC, PBLS, TNGX, and VKTX

Should you buy Oric Pharmaceuticals stock or one of its competitors? MarketBeat compares Oric Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oric Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), Parabilis Medicines (PBLS), Tango Therapeutics (TNGX), and Viking Therapeutics (VKTX). These companies are all part of the "biotechnology" industry.

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Oric Pharmaceuticals presently has a consensus price target of $19.27, suggesting a potential upside of 42.76%. ACADIA Pharmaceuticals has a consensus price target of $33.44, suggesting a potential upside of 14.49%. Given Oric Pharmaceuticals' higher possible upside, equities analysts plainly believe Oric Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, ACADIA Pharmaceuticals had 21 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 12 mentions for Oric Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of 0.27 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	12 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Oric Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
ACADIA Pharmaceuticals	$1.07B	4.70	$391M	$2.22	13.16

Summary

ACADIA Pharmaceuticals beats Oric Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Celcuity?

Oric Pharmaceuticals (NASDAQ:ORIC) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Oric Pharmaceuticals and 7 mentions for Celcuity. Oric Pharmaceuticals' average media sentiment score of 0.27 beat Celcuity's score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Celcuity is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Oric Pharmaceuticals currently has a consensus price target of $19.27, suggesting a potential upside of 42.76%. Celcuity has a consensus price target of $155.18, suggesting a potential upside of 67.24%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oric Pharmaceuticals' return on equity of -35.35% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Celcuity	N/A	-244.61%	-50.22%

Summary

Oric Pharmaceuticals beats Celcuity on 10 of the 13 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Parabilis Medicines?

Oric Pharmaceuticals (NASDAQ:ORIC) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Oric Pharmaceuticals had 12 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for Oric Pharmaceuticals and 0 mentions for Parabilis Medicines. Oric Pharmaceuticals' average media sentiment score of 0.27 beat Parabilis Medicines' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Parabilis Medicines	Neutral

Oric Pharmaceuticals presently has a consensus target price of $19.27, suggesting a potential upside of 42.76%. Parabilis Medicines has a consensus target price of $41.67, suggesting a potential upside of 19.12%. Given Oric Pharmaceuticals' higher probable upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Parabilis Medicines' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Parabilis Medicines	N/A	N/A	N/A

Summary

Oric Pharmaceuticals beats Parabilis Medicines on 6 of the 10 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Tango Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Oric Pharmaceuticals currently has a consensus price target of $19.27, suggesting a potential upside of 42.76%. Tango Therapeutics has a consensus price target of $42.15, suggesting a potential upside of 55.72%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Oric Pharmaceuticals' return on equity of -35.35% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Tango Therapeutics	N/A	-41.54%	-33.44%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tango Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Tango Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Tango Therapeutics	$62.38M	62.77	-$101.59M	-$0.83	N/A

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for Oric Pharmaceuticals and 7 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.81 beat Oric Pharmaceuticals' score of 0.27 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Summary

Tango Therapeutics beats Oric Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Viking Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 12 articles in the media. Viking Therapeutics' average media sentiment score of 1.12 beat Oric Pharmaceuticals' score of 0.27 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oric Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Oric Pharmaceuticals currently has a consensus target price of $19.27, indicating a potential upside of 42.76%. Viking Therapeutics has a consensus target price of $97.88, indicating a potential upside of 185.68%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oric Pharmaceuticals' return on equity of -35.35% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Viking Therapeutics	N/A	-94.56%	-82.75%

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Summary

Oric Pharmaceuticals beats Viking Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.40B	$3.69B	$7.03B	$13.01B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-10.00	5.26	212.02	20.44
Price / Sales	N/A	1,278.69	595.03	84.65
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	3.46	17.61	11.21	6.43
Net Income	-$129.47M	-$13.25M	$3.45B	$348.10M
7 Day Performance	21.95%	6.24%	4.67%	4.41%
1 Month Performance	23.40%	-3.50%	-1.28%	-1.11%
1 Year Performance	46.10%	61.28%	77.33%	23.99%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	2.2882 of 5 stars	$13.50 +4.4%	$19.27 +42.8%	+46.1%	$1.40B	N/A	N/A	80	Earnings Report Upcoming Earnings Options Volume
ACAD ACADIA Pharmaceuticals	4.2984 of 5 stars	$25.61 -1.0%	$32.31 +26.1%	+18.7%	$4.43B	$1.07B	11.64	510	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
CELC Celcuity	2.345 of 5 stars	$87.72 +1.6%	$155.18 +76.9%	+102.2%	$4.21B	N/A	N/A	40	Upcoming Earnings
PBLS Parabilis Medicines	2.4675 of 5 stars	$33.96 -0.1%	$41.67 +22.7%	N/A	$4.01B	N/A	N/A	N/A	Positive News
TNGX Tango Therapeutics	2.5144 of 5 stars	$27.21 +0.1%	$42.15 +54.9%	+309.5%	$3.93B	$62.38M	N/A	90	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. ACAD, CELC, PBLS, TNGX, and VKTX

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to Celcuity?

Summary

How does Oric Pharmaceuticals compare to Parabilis Medicines?

Summary

How does Oric Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. ACAD, CELC, PBLS, TNGX, and VKTX

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Do analysts recommend ORIC or ACAD?

Does the media refer more to ORIC or ACAD?

Which has more risk and volatility, ORIC or ACAD?

Is ORIC or ACAD more profitable?

Do institutionals & insiders have more ownership in ORIC or ACAD?

Which has higher earnings and valuation, ORIC or ACAD?

Summary

How does Oric Pharmaceuticals compare to Celcuity?

Do institutionals and insiders have more ownership in ORIC or CELC?

Does the media prefer ORIC or CELC?

Which has more risk & volatility, ORIC or CELC?

Which has preferable valuation and earnings, ORIC or CELC?

Do analysts recommend ORIC or CELC?

Is ORIC or CELC more profitable?

Summary

How does Oric Pharmaceuticals compare to Parabilis Medicines?

Does the media refer more to ORIC or PBLS?

Do analysts prefer ORIC or PBLS?

Which has stronger earnings & valuation, ORIC or PBLS?

Do insiders and institutionals have more ownership in ORIC or PBLS?

Is ORIC or PBLS more profitable?

Summary

How does Oric Pharmaceuticals compare to Tango Therapeutics?

Do analysts prefer ORIC or TNGX?

Is ORIC or TNGX more profitable?

Do insiders & institutionals have more ownership in ORIC or TNGX?

Which has better valuation & earnings, ORIC or TNGX?

Does the media prefer ORIC or TNGX?

Which has more risk and volatility, ORIC or TNGX?

Summary

How does Oric Pharmaceuticals compare to Viking Therapeutics?

Does the media refer more to ORIC or VKTX?

Do insiders and institutionals have more ownership in ORIC or VKTX?

Which has more risk & volatility, ORIC or VKTX?

Do analysts prefer ORIC or VKTX?

Is ORIC or VKTX more profitable?

Which has stronger earnings and valuation, ORIC or VKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools